AstraZeneca Touts Drug Pipeline Amid Pfizer Bid Speculation
The CEO of AstraZeneca PLC said Tuesday the drugmaker has a strong pipeline of medicines and aims to raise its revenue by three quarters to $45 billion by 2023, puffing up...To view the full article, register now.
Already a subscriber? Click here to view full article